NasdaqGS:SNDXBiotechs
How Investors May Respond To Syndax Pharmaceuticals (SNDX) Shelf Offering And Revuforj Niktimvo Momentum
In late February 2026, Syndax Pharmaceuticals filed a US$77.73 million shelf registration for 3,746,239 common shares tied to an ESOP-related offering and scheduled Q4 2025 results alongside a TD Cowen healthcare conference presentation by CEO Michael A. Metzger.
Management’s recent conference remarks emphasized strong commercial traction for Revuforj in KMT2A-rearranged AML and a large chronic graft-versus-host disease opportunity for Niktimvo, supported by a collaboration with...